Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

SLRN

ACELYRIN (SLRN)

ACELYRIN Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SLRN
DateTimeSourceHeadlineSymbolCompany
04/04/20253:34PMGlobeNewswire Inc.Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed MergerNASDAQ:SLRNACELYRIN Inc
04/04/20253:28PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SLRNACELYRIN Inc
04/04/20253:22PMEdgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:SLRNACELYRIN Inc
03/19/20254:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
03/19/20253:32PMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SLRNACELYRIN Inc
03/19/20253:12PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLRNACELYRIN Inc
03/19/20253:04PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SLRNACELYRIN Inc
03/18/20255:02AMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SLRNACELYRIN Inc
03/13/20258:37AMEdgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NASDAQ:SLRNACELYRIN Inc
03/13/20258:32AMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SLRNACELYRIN Inc
03/13/20258:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
03/13/20256:00AMGlobeNewswire Inc.ACELYRIN Adopts Limited-Duration Stockholder Rights PlanNASDAQ:SLRNACELYRIN Inc
03/06/202510:55AMEdgar (US Regulatory)Form SCHEDULE 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:SLRNACELYRIN Inc
03/06/20255:05AMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SLRNACELYRIN Inc
03/06/20255:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
03/04/20258:07AMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SLRNACELYRIN Inc
03/04/20258:05AMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SLRNACELYRIN Inc
03/04/20258:01AMGlobeNewswire Inc.ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed MergerNASDAQ:SLRNACELYRIN Inc
03/04/20258:01AMGlobeNewswire Inc.Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed MergerNASDAQ:SLRNACELYRIN Inc
03/04/20258:00AMGlobeNewswire Inc.ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis MergerNASDAQ:SLRNACELYRIN Inc
02/21/202512:17PMPR Newswire (US)Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law FirmNASDAQ:SLRNACELYRIN Inc
02/21/20255:03AMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SLRNACELYRIN Inc
02/20/20258:00PMGlobeNewswire Inc.ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra BiosciencesNASDAQ:SLRNACELYRIN Inc
02/10/20258:11AMPR Newswire (US)Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law FirmNASDAQ:SLRNACELYRIN Inc
02/07/20254:00PMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SLRNACELYRIN Inc
02/07/20252:22PMPR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.NASDAQ:SLRNACELYRIN Inc
02/06/20254:19PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
02/06/20253:15PMGlobeNewswire Inc.Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated DiseasesNASDAQ:SLRNACELYRIN Inc
02/06/20253:15PMGlobeNewswire Inc.Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated DiseasesNASDAQ:SLRNACELYRIN Inc
01/31/20253:26PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
 Showing the most relevant articles for your search:NASDAQ:SLRN